Primecap Management Co. CA Has $12.94 Billion Holdings in Eli Lilly and Company (NYSE:LLY)

Primecap Management Co. CA trimmed its position in Eli Lilly and Company (NYSE:LLY) by 3.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,200,534 shares of the company’s stock after selling 863,002 shares during the quarter. Eli Lilly and Company makes up approximately 10.2% of Primecap Management Co. CA’s holdings, making the stock its largest position. Primecap Management Co. CA owned 2.34% of Eli Lilly and Company worth $12,941,135,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in Eli Lilly and Company during the 4th quarter worth $5,992,890,000. International Assets Investment Management LLC boosted its position in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth $682,139,000. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the 3rd quarter worth $435,736,000. Finally, Vanguard Group Inc. boosted its position in Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LLY shares. BMO Capital Markets boosted their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Argus upped their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a report on Wednesday, February 21st. Finally, Morgan Stanley upped their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $769.53.

Eli Lilly and Company Stock Down 0.1 %

Shares of NYSE LLY traded down $1.02 during mid-day trading on Friday, reaching $807.43. The company had a trading volume of 1,758,200 shares, compared to its average volume of 2,993,883. The stock has a fifty day moving average of $765.47 and a two-hundred day moving average of $692.32. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company has a market capitalization of $767.39 billion, a price-to-earnings ratio of 118.91, a PEG ratio of 1.75 and a beta of 0.37. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $820.60.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.62 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 13.78 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.